EUVIMEDEUVIMED entdecken
Crossref

Early B Cell Factor 3 (EBF3) attenuates Parkinson's disease through directly regulating contactin-associated protein-like 4 (CNTNAP4) transcription: An experimental study

Wentao Hu, Menghan Wang, Guifang Sun, Limin Zhang, Hong Lu

Cellular Signalling · 2024

DOI: 10.1016/j.cellsig.2024.111139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Signalling, 2024. Verfasst von Wentao Hu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China. Electronic address: fcchuwt@zzu.edu.c…. Hauptthemen laut MEDLINE: Neuroblastoma, Parkinson Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson's disease (PD) is a gradually debilitating neurodegenerative syndrome. Here, we analyzed GSE7621 chip data obtained from the Gene Expression Omnibus (GEO) database to explore the pathogenesis of PD. Early B Cell Factor 3 (EBF3), a member of the highly evolutionarily conserved EBF-transcription factor family, is involved in neuronal development. EBF3 expression is low in the substantia nigra of patients with PD. However, whether EBF3 is implicated in dopaminergic neuron death during PD has not yet been investigated. Therefore, we aimed to reveal the potential anti-apoptotic effect and molecular mechanism of EBF3 in PD. We established a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model in vivo and a 1-methyl-4-phenylpyridine (MPP+)-induced SH-SY5Y cell model in vitro. EBF3 was downregulated in the substantia nigra of PD mice and SH-SY5Y cells treated with MPP+, and the m6A methylation modification level was low. Fat mass and obesity-associated protein (FTO) siRNA upregulated m6A methylation modification of EBF3 and extended the EBF3 mRNA half-life. Functionally, as demonstrated by the results of the open-field test, pole test and gait analysis, EBF3 overexpression ameliorated MPTP-induced behavioral disorder. Further, EBF3 overexpression suppressed neuronal apoptosis in vivo, as evidenced by decreased TUNEL+ cells, and the increased activation of caspase-3 and caspase-9. Similar results were obtained in vitro, as reflected by increased cell viability, decreased LDH activity and restored mitochondrial function, collectively protecting SH-SY5Y cells from MPP+-induced apoptosis. Mechanistically, the results of luciferase reporter, ch-IP and DNA pull-down assays confirmed that, as a transcription factor, EBF3 bound to the promoter of CNTNAP4 (a protein associated with neuronal differentiation) and directly regulated CNTNAP4 transcription. Strikingly, CNTNAP4 knockdown markedly abolished the effect of EBF3 on cell apoptosis, thus aggravating PD. In conclusion, the low level of m6A methylation modification may contribute to the low expression of EBF3 during PD. Additionally, EBF3 attenuates PD by activating CNTNAP4 transcription, suggesting that EBF3 may be a novel therapeutic target in PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaParkinson DiseaseAnimalsHumansMiceAlpha-Ketoglutarate-Dependent Dioxygenase FTOApoptosisCell Line, TumorContactinsDopaminergic NeuronsMice, Inbred C57BLTranscription FactorsNerve Tissue ProteinsMembrane Proteins

Stichwörter der Autor:innen

CNTNAP4EBF3FTONeuronal apoptosisParkinson's disease

Substanzen

Alpha-Ketoglutarate-Dependent Dioxygenase FTOContactinsTranscription FactorsEBF3 protein, humanFTO protein, humanCNTNAP4 protein, humanNerve Tissue ProteinsCntnap4 protein, mouseMembrane Proteins

Autor:innen und Institutionen

  • Department of Neurology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China. Electronic address: fcchuwt@zzu.edu.cn.
  • Department of Neurology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.
  • Department of Neurology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China. Electronic address: zzu_luhong@163.com.

Zitieren

APA

Hu, W., Wang, M., Sun, G., Zhang, L., & Lu, H. (2024). Early B Cell Factor 3 (EBF3) attenuates Parkinson's disease through directly regulating contactin-associated protein-like 4 (CNTNAP4) transcription: An experimental study. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2024.111139

Vancouver

Hu W, Wang M, Sun G, Zhang L, Lu H. Early B Cell Factor 3 (EBF3) attenuates Parkinson's disease through directly regulating contactin-associated protein-like 4 (CNTNAP4) transcription: An experimental study. Cellular Signalling. 2024. doi:10.1016/j.cellsig.2024.111139

BibTeX
@article{Hu2024,
  author = {Hu, Wentao and Wang, Menghan and Sun, Guifang and Zhang, Limin and Lu, Hong},
  title = {Early B Cell Factor 3 (EBF3) attenuates Parkinson's disease through directly regulating contactin-associated protein-like 4 (CNTNAP4) transcription: An experimental study},
  journal = {Cellular Signalling},
  year = {2024},
  doi = {10.1016/j.cellsig.2024.111139}
}
Kostenlos starten →